Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Lucentis (Ranibizumab) Market Revenue Growth Supported By A CAGR Of % Through 2030
The market for Lucentis (ranibizumab) has experienced robust expansion in recent times. Its valuation is projected to rise from $3.74 million in 2025 to $3.96 million in 2026, reflecting a compound annual growth rate (CAGR) of 5.7%. This upward trend during the historical period has been driven by clinical achievements in treating macular degeneration, an increase in diabetic retinopathy incidences, a growing elderly demographic, heightened acceptance among ophthalmologists, and the receipt of regulatory approvals within the ophthalmic field.
The market for Lucentis (ranibizumab) is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $4.87 million, reflecting a compound annual growth rate (CAGR) of 5.4%. This upward trajectory during the forecast period is driven by several factors, including a rise in retinal disease prevalence, improved access to eye care services, the growing presence of biosimilar competition, heightened awareness regarding early diagnosis, and advancements in injection delivery technologies. Key trends shaping this period involve the continued application of anti-VEGF therapies, an increase in treatments for retinal vascular disorders, a growing preference for intravitreal injections, the proliferation of specialized ophthalmology clinics, and a stronger emphasis on preserving vision.
Download A Free Sample Report For Comprehensive Market Insights:
Lucentis (Ranibizumab) Market Growth Drivers And Industry Catalysts
The growing incidence of eye-related conditions is anticipated to boost the Lucentis (ranibizumab) market in the coming period. Eye-related disorders encompass a broad spectrum of diseases or states that impair normal vision or eye function. This increasing occurrence is driven by aging, hereditary factors, unhealthy habits like smoking and poor nutrition, as well as environmental influences such as extended screen time or sun exposure. Lucentis functions by blocking vascular endothelial growth factor (VEGF), a protein that triggers abnormal retinal blood vessel formation and leakage, which underlies diseases like age-related macular degeneration (AMD) and diabetic macular edema (DME). As an example, the National Eye Institute, a U.S. government agency, reported in 2024 that 2.2 million Americans will experience blindness by 2030. Consequently, the rising frequency of eye disorders is fueling expansion in the Lucentis (ranibizumab) market.
Increasing healthcare expenditure is set to accelerate growth in the lucentis (ranibizumab) market in the future. Healthcare spending denotes the total financial commitment made by individuals, governments, private insurers, and other bodies toward medical services and products. This uptick is linked to an aging population, technological progress in medicine, a higher prevalence of chronic illnesses, and greater demand for care. Such investment enhances the availability and accessibility of lucentis (ranibizumab) by facilitating its broad use in treating retinal conditions like age-related macular degeneration and diabetic macular edema, allowing healthcare systems to fund its reimbursement, coverage, and distribution, thereby improving patient outcomes and lessening the long-term impact of vision impairment. For instance, data from the Office for National Statistics, a UK government department, showed that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to 0.9% growth in 2022, reaching roughly $317.63 billion (£292 billion) in 2023. Thus, escalating healthcare expenditure is driving the growth of the lucentis (ranibizumab) market.
Lucentis (Ranibizumab) Market Segmentation: How Is The Market Structured Across Key Categories?
The lucentis (ranibizumab) market covered in this report is segmented –
1) By Type: Single-use Prefilled Syringe, Single-use Glass Vial
2) By Application: Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Myopic Choroidal Neovascularization, Uveitis
3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users
Lucentis (Ranibizumab) Market Trends Influencing Long-Term Demand
Major players within the Lucentis (ranibizumab) market are actively pursuing the development of biosimilars aimed at offering cost-effective substitutes for the original branded medication. These biosimilars consist of biologic products that closely resemble an already approved reference biologic in structure, effectiveness, and safety, without any significant clinical differences. For example, in April 2024, Formycon AG, a biotechnology firm from Germany, together with Bioeq AG, a biotechnology enterprise based in Switzerland, introduced their biosimilar version of Lucentis known as FYB201 in Canada and Switzerland. Marketing authorization was granted by Health Canada under the brand name Ranopto, while Swiss Medic approved it as Ranivisio. The approval and subsequent rollout of FYB201 are intended to deliver more accessible treatment options for individuals dealing with retinal conditions. This medication functions by blocking vascular endothelial growth factor A (VEGF-A), a protein that facilitates abnormal blood vessel formation in the retina, potentially resulting in swelling, leakage, and compromised vision.
Lucentis (Ranibizumab) Market Competitive Landscape And Leading Companies
Major companies operating in the lucentis (ranibizumab) market are F.Hoffmann-La Roche Ltd, Novartis AG
Access The Complete Lucentis (Ranibizumab) Market Report:
Lucentis (Ranibizumab) Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the lucentis (ranibizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lucentis (ranibizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model